View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 25, 2022

The shift of environmental, social, and governance issues in medical device companies

Taking action against climate action can attract more customers, partners, and employees as it is becoming a competitive differentiator.

By GlobalData Healthcare

Environmental, social, and governance (ESG) issues in a post-pandemic world will drive corporate strategies and operational decisions. For example, companies will need to address issues such as social inequality, climate change, and tax avoidance. According to the GlobalData ESG Strategy Survey 2021, 70% of 1,500 ESG executives believe that setting ESG goals will positively impact company revenue. This same survey demonstrated that 80% of companies plan to increase the allocation of their investments to meet ESG targets.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Taking action against climate action can attract more customers, partners, and employees as it is becoming a competitive differentiator. Hundreds of companies are committing to reach net-zero carbon emissions in the next 20 to 30 years. GlobalData expects that this process will speed up as climate change pioneers demonstrate that decarbonisation is both possible and brings market value. Companies are focusing on three different scopes. Scope one and two refer to direct and indirect emissions from company-owned or -controlled sources, and scope three refers to all other indirect emissions in the company’s value chain. For example, Thermo Fisher Scientific announced in July 2021 that it is committed to achieving net-zero carbon emissions by 2050. Thermo Fisher Scientific executives emphasised that achieving carbon neutrality is essential in enabling their customers to make the world healthier, cleaner, and safer.

Companies need to consider social factors to drive business decisions. Since 2020, the Covid-19 pandemic, and the growing emphasis on social justice, have highlighted the drawbacks of unsustainable social practices and the need to integrate more socially sustainable practices. The four main factors to social challenges are human rights, diversity and inclusion, health and safety, and community impact. Stakeholders are demanding increased transparency and accountability from companies, which is helping to drive the needed social change. For example, Bristol Myers Squibb announced this month that it will be providing $7.965 million in new health equality grants to 24 US non-profit organisations to improve access to and quality of care for medically under served patients and communities.

Governance failures, such as bribery and corruption, damage a company’s reputation and cause a loss of trust. The four pillars determining good governance are corporate structure, risk management, corruption and bribery, and ethics. Governance is the determining factor on whether a company can deliver results to its stakeholders. Since the new generation of consumers has a greater sense of global responsibility, companies need to be transparent and prioritise their ESG strategies. AB InBev uses an artificial intelligence (AI) system, BrewRight, to expose and eliminate corruption and fraud before it takes place. The technology searches for patterns in transactions to identify anomalies and fraud risk across the company’s enterprise-resource planning systems. Moreover, a 2019 survey conducted by the Association of Certified Fraud Examiners found that 13% of companies are using AI systems to detect fraud. Therefore, many companies have room to grow in the prevention of corruption and other governance issues.

GlobalData believes that prioritising ESG-focused strategic plans is vital when building a new virtuous cycle, where pressure from stakeholders will allow for positive changes in ESG issues. This will result in more investments into companies that prioritise solving ESG issues, and will have an increasing impact on market performance.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network